FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $692.42M

Company

Location

Date

Amt. (M)

Details


Aegera
Therapeutics
Inc.

Montreal

11/20/06

$21

The Series C round included a $14M equity financing and a $7M debt facility; VenGrowth Advanced Life Sciences Fund Inc. led the financing, which included GrowthWorks, Business Development Bank of Canada, Desjardins Venture Capital, Multiple Capital and Solidarity Fund

Alba
Therapeutics
Corp.

Baltimore

11/27/06

$10

A $10M debt commitment was provided by a syndicate consisting of Atel Ventures Inc., Oxford Finance Corp. and SVB Silicon Valley Bank

Alimera
Sciences Inc.

Atlanta

11/27/06

$15.9

Alimera added $15.9M to the $31.8M raised in 2005 in the first part of its Series B financing; investors in both tranches included BA Venture Partners, Domain Associates, Intersouth Partners, Polaris Venture Partners and Venrock Associates

AnaMar
Medical AB

Goteborg, Sweden

11/16/06

SEK50 ($7.1)

The company's larget shareholder, Koncentra Holding AB, is providing the SEK50M investment; LinkMed AB, the second largest stockholder, has an option to invest SEK7.5M

AmpliMed Corp.

Tucson, Ariz.

11/28/06

$8.5

AmpliMed raised $8.5M in the second tracnhe of a Series B financing, bringing the round to about $14.6M; the investment was led by Biotech Insight Ventures and other existing investors InvestBio Ventures, Valley Ventures and Solstice Capital

Cara
Therapeutics
Inc.

Tarrytown, N.Y.

11/28/06

$19

The Series C financing included new investors MVM Life Science Partners and Alta Biopharma Partners, and existing investor Ascent Biomedical Ventures

Cerenis
Therapeutics
Inc.

Ann Arbor, Mich., and Toulouse, France

1/13/06

$53.5

The Series B financing was led by TVM Capital, which was joined by OrbiMed and previous investors Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures and NIF SMBC Ventures

Chiasma Inc.

Boston

11/15/06

$44

The Series C financing was led by MPM Capital, with participation by ARCH Venture Partners and existing investors Ofer Hi-tech Group and F-2 Ventures

Concert
Pharmaceuticals
Inc.

Lexington, Mass.

11/30/06

$48.5

The Series B financing was led by new investor Flagship Ventures and included Brookside Capital Partners Fund LP and New Leaf Venture Partners, as well as existing investors Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners and QVT Fund LP

Elixir
Pharmaceuticals
Inc.

Cambridge, Mass.

11/28/06

$46

The Series C round included $31M in equity and $15M in debt; the equity portion was led by MPM Capital and included existing investors ARCH Venture Partners and Oxford BioScience Partners, and new investors CDIB, JAFCO and YFY Bio- science; Hercules Technology Growth Capital Inc. provided the debt funding

ERA Biotech

Barcelona, Spain

11/30/06

|1.4($1.9)

Invertec, Reus Capital Riesgo, Talde Capial II and Uninvest each provided |0.3M in convertible loans to lead the seed funding round

EyeGate
Pharma*

Paris

11/2/06

$10

The Series B financing round was co-led by Innoven Partenaires and Ventech

Intradigm
Corp.

Palo Alto, Calif.

11/21/06

$16

The Series A financing was co-led by Alta Partners and Frazier Healthcare Ventures, and included existing investors Emerging Technology Partners and Novartis' Ventures Fund, and new investors MediBic Alliance/Daiichi and Genentech Corp.

Kalypsys Inc.

San Diego

11/29/06

$100

The $100M Series C financing round included an $89M investment by existing investor Tavistock Life Sciences; existing investors also participat- ing were Sprout Group, CMEA Ventures and KT Venture Group

MedGenesis
Therapeutix
Inc.

Victoria, British Columbia

11/8/06

$3.2

Details on the equity financing were not disclosed

Merrion
Pharmaceuticals
Ltd.

Dublin, Ireland

11/29/06

|8 (10.6)

About |6M of the financing round was provided earlier in the year by existing investors; Goodbody Stockbrokers managed the deal

Myconostica
Ltd.

Manchester, UK

11/27/06

£1 ($1.96)

Amphon Innovations plc provided funding for the University of Manchester spinoff

Neurotech
Pharmaceuticals
Inc.

Lincoln, R.I.

11/16/06

$35

The Series B financing was led by Burrill and Co., with participation from Versant Ventures and SV Life Sciences; other new investors were Omega Fund, Nexus Medical Partners and Pound Capital, which joined existing investors Apax Partners France, Merlin Biosciences, Atlas Venture, Mayflower, Avida Group and Alpha Associates

Orexigen
Therapeutics
Inc.

San Diego

11/22/06

$30

New investors MPM BioEquities and Wasatch Advisors joined existing investors in the Series C financing round

Palau Pharma

Barcelona, Spain

11/1/06

|40($52.5)

The company was spun out of Grupo Uriach's R&D unit; acquiring a minority stake in Palau in the intial funding were Invercartera, Caja Duero, the Cerqueda family and Najeti Capital

PharmaKodex
Ltd.

Chippenham, UK

11/16/06

£7.1($13.6)

The Series A financing round was co-led by Apposite Capital and SR One Ltd.; Unilever Ventures and Vectura Group plc also participated

Renovar Inc.

Madison, Wis.

11/30/06

$1.22

Investing the second-round financing were NEW Capital Fund LP, Wisconsin Investment Partners and individuals, including the company's CEO

Solstice
Neurosciences
Inc.

Malvern, Pa.

11/8/06

$85

The $85M included a Series B investment and a debt financing; Highland Capital Management LP led the Series B round, which included Series A investors Thomas, McNerney & Partners; Investor Growth Capital Inc.; Morgan Stanley Venture Partners; and Oxford Bioscience Partners

TetraPhase
Pharmaceuticals
Inc.

Watertown, Mass.

11/27/06

$25

Investors in the Series A financing included Mediphase Venture Partners, Fidelity Biosciences, Skyline Ventures, Flagship Ventures and CMEA Ventures

Xanthus
Pharmaceuticals
Inc.

Cambridge, Mass.

11/30/06

$25

The Series B financing was provided by existing investors Oxford Bioscience Partners, HealthCare Ventures, GeneChem, GIMV, Hambrecht & Quist Capital Management, Still River Fund, Neomed, Kestrel Ventures, CDP Capital, CDIB BioScience Ventures and Yasuda

Xceleron Ltd.

York, UK

11/30/06

£2($3.94)

Close Ventures provided £1.5M of the funding; the balance was provided by Foursome Investments along with company directors and management

Yaupon
Therapeutics
Inc.

Radnor, Pa.

11/13/06

$4

The Series B financing was led by Osage Ventures and included the BioAdvance Greenhouse Fund, Ben Franklin Technology Partners and TDH Capital


Notes:

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.